Stock Events

Stock Events

Deciphera Pharmaceuticals 

$25.59
13
+$0.02+0.08% Monday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

10MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.62
-0.59
-0.55
-0.52
Expected EPS
-0.55
Actual EPS
-0.52

Financials

-119.34%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
163.36MRevenue
-194.94MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DCPH. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap1.2B
Array BioPharma, acquired by Pfizer, works on targeted small molecule drugs to treat cancer, including kinase inhibitors that compete with Deciphera's products.
AMGEN
AMGN
Mkt Cap178B
Amgen has a broad oncology portfolio, including treatments that target similar pathways and mechanisms as Deciphera's kinase inhibitors.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a diverse oncology portfolio, including kinase inhibitors, directly competing with Deciphera in the cancer treatment space.
Novartis
NVS
Mkt Cap279.67B
Novartis offers targeted oncology treatments, including kinase inhibitors, competing in the same therapeutic areas as Deciphera.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb has a strong presence in oncology, with a portfolio that includes kinase inhibitors, making it a direct competitor.
Merck
MRK
Mkt Cap277.02B
Merck's focus on cancer treatments, including targeted therapies, places it in competition with Deciphera for market share in oncology.
Exelixis
EXEL
Mkt Cap11.1B
Exelixis is focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers, competing with Deciphera's niche.
Incyte
INCY
Mkt Cap19.36B
Incyte's work on novel cancer therapies, including kinase inhibitors, pits it against Deciphera in the oncology market.

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Steven Hoerter
Employees
355
Country
United States
ISIN
US24344T1016
WKN
000A2H48H

Listings

0 Comments

Share your thoughts

FAQ

What is Deciphera Pharmaceuticals stock price today?▼
The current price of DCPH is $25.59 USD — it has increased by +0.08% in the past 24 hours. Watch Deciphera Pharmaceuticals stock price performance more closely on the chart.
What is Deciphera Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Deciphera Pharmaceuticals stocks are traded under the ticker DCPH.
What were Deciphera Pharmaceuticals earnings last quarter?▼
DCPH earnings for the last quarter are -0.52 USD per share, whereas the estimation was -0.55 USD resulting in a +5.45% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Deciphera Pharmaceuticals revenue for the last year?▼
Deciphera Pharmaceuticals revenue for the last year amounts to 163.36M USD.
What is Deciphera Pharmaceuticals net income for the last year?▼
DCPH net income for the last year is -194.94M USD.
How many employees does Deciphera Pharmaceuticals have?▼
As of May 06, 2026, the company has 355 employees.
In which sector is Deciphera Pharmaceuticals located?▼
Deciphera Pharmaceuticals operates in the Technology sector.
When did Deciphera Pharmaceuticals complete a stock split?▼
Deciphera Pharmaceuticals has not had any recent stock splits.
Where is Deciphera Pharmaceuticals headquartered?▼
Deciphera Pharmaceuticals is headquartered in Waltham, United States.